# Charity Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/charity-biotech

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Website: www.charitybiotech.cn
- Latest round: Series B (Apr 15, 2025)
- Investors on record: 1

## About

Founded in 2020 and headquartered in Shanghai, China, Charity Biotech focuses on advancing blood purification technologies and establishing the PEDAC system platform for clinical applications. The company is committed to developing innovative solutions that address unmet medical needs in patient care. Charity Biotech’s core product, developed from the PEDAC treatment system, is the "Uric Acid Directed Adsorption Hemoperfusion Device." This device is designed for gout patients, particularly those with tophi, to significantly reduce serum uric acid levels within a short period, helping to treat gout and dissolve tophaceous deposits. The company also develops adsorption materials and systems that enable the targeted clearance of harmful blood components for therapeutic use. The company generates revenue from the development, production, and sales of blood purification devices and consumables, particularly those applied in the treatment of gout and related metabolic disorders.
In April 2025, Charity closed a venture funding from new investor Watere Capital.

## Funding rounds

- Series B, Apr 15, 2025 — Watere Capital

## Investors

- Watere Capital (https://capitalatlas.ai/funds/watere-capital) — Series B